variable Total(n=96) No CAEs(n=78) CAEs(n=18) p
Age(y) 49.7±11.8 49.4±11.3 50.8±14.0 .725
Men 57(60%) 45(58%) 12(67%) .485
Weight(kg) 65±9.8 64±10 65±8 .894
Follow-up period(d) 2242±281 2248±280 2213±292 .596
Cycles of R-CHOP 5.4±1.3 5.4±1.4 5.5±1.3 .706
Cumulative dose of doxorubin (mg/m2) 379.9±94.0 378.7±94.7 385.0±93.8 .706
Cardiac risk factors
BP>140/90mm Hg 15(16%) 12(15%) 3(17%) 1.000
Diabetes mellitus 6(6%) 4(5%) 2(10%) .685
Smoking 29(30%) 23(29%) 6(33%) .749
Cancer
I,II 78(81%) 58(74%) 14(78%) 1.000
III,IV 18(19%) 20(26%) 4(22%)
ECOGPS 0.49±0.54 0.46±0.55 0.61±0.50 .246
Baseline 3D Echocardiography before chemotherapy Baseline 3D Echocardiography before chemotherapy Baseline 3D Echocardiography before chemotherapy Baseline 3D Echocardiography before chemotherapy Baseline 3D Echocardiography before chemotherapy
Left ventricular parameters
LVEF(%) 59.6±5.0 59.4±4.9 60.3±5.7 .527
LVEDV 73.7±13.0 72.9±12.0 77.1±16.7 .368
LVESV 29.7±7.0 29.6±6.3 30.2±9.8 .740
GLS 20.8±2.6 20.8±2.3 20.8±3.7 .980
GCS 28.1±3.9 27.9±3.5 28.9±5.5 .487
Right ventricular parameters
RVEF(%) 50.7±4.2 50.9±4.1 49.8±4.7 .314
RVEDV 63.2±13.1 61.8±11.2 69.2±18.4 .117
RVESV 31.7±8.1 30.4±6.2 37.8±12.2 .017